Steroid-free maintenance immunosuppression and ABO-incompatible transplantation

Transplantation

Volumn 89, Issue 6, 2010, Pages 648-649

  Gloor, James ^a   Matas, Arthur J ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

BLOOD GROUP ABO INCOMPATIBILITY; GLOMERULOPATHY; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; NOTE; PRIORITY JOURNAL; RISK FACTOR;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; ADMINISTRATION, ORAL; BIOPSY; BLOOD GROUPING AND CROSSMATCHING; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; PATIENT SELECTION; PREDNISONE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949911028     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c9cc97     Document Type: Note

References (5)

1. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009; 22: 38.
2. KatoY, TojimbaraT, IwadohK, et al. Early steroid withdrawal protocol with basiliximab, cyclosporine, and mycophenolate mofetil in renal transplant recipients. Int Immunopharmacol 2006; 6: 1984.
3. Galliford J, Charif R, Chan KK, et al. ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation 2008; 7: 901.
4. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
5. Toki D, IshidaH, SetoguchiK, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: Long-term impact and risk factors. Am J Transplant 2009; 9: 567.